Price
CHART BY
Frequently asked questions
What is Harmony Hldg's market capitalization?
The market capitalization of Harmony Hldg is $2.36B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Harmony Hldg's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Harmony Hldg is 13.12. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Harmony Hldg?
Harmony Hldg's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $3.086. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Harmony Hldg's stock?
Currently, 11 analysts cover Harmony Hldg's stock, with a consensus target price of $47.36. Analyst ratings provide insights into the stock's expected performance.
What is Harmony Hldg's revenue over the trailing twelve months?
Over the trailing twelve months, Harmony Hldg reported a revenue of $959.90M.
What is the EBITDA for Harmony Hldg?
Harmony Hldg's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $255.99M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Harmony Hldg?
Harmony Hldg has a free cash flow of $354.90M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Harmony Hldg have, and what sector and industry does it belong to?
Harmony Hldg employs approximately 293 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Harmony Hldg's shares?
The free float of Harmony Hldg is 50.20M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.36B
- EPS (TTM)
- $3.086
- Free Float
- 50.20M
- P/E ratio (TTM)
- 13.12
- Revenue (TTM)
- $959.90M
- EBITDA (TTM)
- $255.99M
- Free Cashflow (TTM)
- $354.90M
Pricing
- 52W span
- $25.52$43.49
Analyst Ratings
The price target is $47.36 and the stock is covered by 11 analysts.
Buy
7
Hold
3
Sell
1
Information
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
- Employees
- 293
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- HRMY
Fundamentals & EOD data from FactSet